Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Times Interest Earned (2016 - 2026)

Ocular Therapeutix has reported Times Interest Earned over the past 14 years, most recently at -$33.61 for Q1 2026.

  • For Q1 2026, Times Interest Earned fell 56.92% year-over-year to -$33.61; the TTM value through Mar 2026 reached -$25.75, down 57.87%, while the annual FY2025 figure was -$22.82, 80.32% down from the prior year.
  • Times Interest Earned for Q1 2026 was -$33.61 at Ocular Therapeutix, down from -$24.63 in the prior quarter.
  • Over five years, Times Interest Earned peaked at -$4.83 in Q4 2023 and troughed at -$33.61 in Q1 2026.
  • A 5-year average of -$15.02 and a median of -$12.75 in 2023 define the central range for Times Interest Earned.
  • Biggest five-year swings in Times Interest Earned: surged 53.92% in 2023 and later crashed 237.12% in 2024.
  • Year by year, Times Interest Earned stood at -$10.48 in 2022, then surged by 53.92% to -$4.83 in 2023, then plummeted by 237.12% to -$16.28 in 2024, then plummeted by 51.28% to -$24.63 in 2025, then crashed by 36.45% to -$33.61 in 2026.
  • Business Quant data shows Times Interest Earned for OCUL at -$33.61 in Q1 2026, -$24.63 in Q4 2025, and -$22.88 in Q3 2025.